Atazanavir: a novel HIV-1 protease inhibitor (Q34841884)

4 August 2017

1 reference

title

Atazanavir: a novel HIV-1 protease inhibitor (English)

1 reference

4 August 2017

1 reference

Peter J Piliero

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

4 August 2017

volume

11

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

1295-1301

1 reference

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

21 January 2018

The retroviral enzymes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

Interaction between ritonavir and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1295

10.1517/13543784.11.9.1295

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference